Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report
oleh: Leonard Kaps, Christian Labenz, Daniel Grimm, Andreas Schwarting, Peter R. Galle, Oliver Schreiner
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2020-12-01 |
Deskripsi
Abstract The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID‐19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.